Vivian Wu | Investor Relations |
Howard Robin | President and Chief Executive Officer |
Jonathan Zalevsky | Chief, Research and Development |
Mary Tagliaferri | Chief Medical Officer |
Sandra Gardiner | Acting Chief Financial Officer |
Jerry Gong | Mizuho |
Daina Graybosch | SVB Securities |
Good day and thank you for standing by. Welcome to the Nektar Therapeutics First Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Vivian Wu. Please go ahead.